
Keywords: AvWS; acquired von Willebrand syndrome; BTT; bridge to transplant; CF; continuous flow; DT; destination therapy; FDA; Food and Drug Administration; GI; gastrointestinal; HF; heart failure; HM; HeartMate; HTx; heart transplant; INR; international normalize